Compare AbCellera Biologics Inc (ABCL) vs Nokia Corp (NOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Nokia Corp — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Nokia Corp trades at $11.75 (market cap $66.24B). The key difference: Nokia Corp is far larger — about 28.2× AbCellera Biologics Inc's market cap, and Nokia Corp pays a 1.38% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NOK | |
|---|---|---|
Market Cap | $2.35B | $66.24B |
Sector | Health | Technology |
52-Week High | $8.12 | $16.83 |
52-Week Low | $2.78 | $4.05 |
Enterprise Value | $1.99B | $63.06B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Nokia (NOK) trades at $11.85, down 1.74% amid a bearish technical signal, despite strong year-to-date performance. The company shows mixed fundamentals with a high P/E of 78.47 but recent earnings beats and a 44.12% gross margin. Recent news highlights Nokia's strategic pivot to AI infrastructure, including partnerships with Nvidia and Amazon Web Services, driving investor optimism about future growth potential in network modernization and data center markets.
Outlook remains cautiously optimistic with a consensus price target of $18.00 representing 52% upside, though high valuation and recent earnings miss pose risks. The stock's direction hinges on execution of AI initiatives and Q2 2026 earnings results due July 23, with technical indicators suggesting near-term consolidation near current support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
